- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.07. | ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operations | ||
| 01.07. | Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering atai merger | ||
| 01.07. | Sanofi takes up option on Adagene biospecific and invests $25M, shielding partner from runway risk | ||
| 01.07. | BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent | ||
| 01.07. | Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blocker | ||
| 30.06. | 'Emergency' at Apple Tree: VC sues key investor, warns portfolio biotechs are on brink of collapse | ||
| 30.06. | Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 | ||
| 30.06. | Pfizer expands AI-powered small-molecule discovery collab with XtalPi | ||
| 30.06. | AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market | ||
| 30.06. | INmune flunks phase 2 Alzheimer's trial, focuses on subgroup efficacy to fuel partnering plans | ||
| 30.06. | Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA | ||
| 30.06. | Pliant ends lung disease program after assessing rise in adverse events from bexotegrast trial | ||
| 27.06. | CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle | ||
| 27.06. | Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout | ||
| 27.06. | Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials | ||
| 26.06. | Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset | ||
| 26.06. | Invivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccines | ||
| 26.06. | Alto misses primary efficacy endpoint in phase 2 depression trial | ||
| 26.06. | Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug | ||
| 26.06. | Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug | ||
| 25.06. | Minovia brings back SPAC with plans to skate into icy public market | ||
| 25.06. | Kymera suffers Sanofi setback but secures $750M Gilead deal | ||
| 25.06. | Arbutus regains China rights to potential functional hep B cure as part of strategic rethink | ||
| 25.06. | Biogen's Spinraza follow-up helps children with SMA who didn't benefit from Zolgensma | ||
| 25.06. | Bayer-owned BlueRock lays off 50 employees, shuts Cambridge research labs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .